| Inherited DNA-repair gene mutations in men with metastatic prostate cancer CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ... New England Journal of Medicine 375 (5), 443-453, 2016 | 1596 | 2016 |
| Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context G Draisma, R Etzioni, A Tsodikov, A Mariotto, E Wever, R Gulati, E Feuer, ... Journal of the National Cancer Institute 101 (6), 374-383, 2009 | 1006 | 2009 |
| Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer A Kumar, I Coleman, C Morrissey, X Zhang, LD True, R Gulati, R Etzioni, ... Nature medicine 22 (4), 369-378, 2016 | 699 | 2016 |
| Quantifying the role of PSA screening in the US prostate cancer mortality decline R Etzioni, A Tsodikov, A Mariotto, A Szabo, S Falcon, J Wegelin, ... Cancer Causes & Control 19, 175-181, 2008 | 509 | 2008 |
| Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials A Tsodikov, R Gulati, EAM Heijnsdijk, PF Pinsky, SM Moss, S Qiu, ... Annals of internal medicine 167 (7), 449-455, 2017 | 268 | 2017 |
| Comparative effectiveness of alternative prostate-specific antigen–based prostate cancer screening strategies: model estimates of potential benefits and harms R Gulati, JL Gore, R Etzioni Annals of internal medicine 158 (3), 145-153, 2013 | 201 | 2013 |
| Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress MD Nyquist, A Corella, I Coleman, N De Sarkar, A Kaipainen, G Ha, ... Cell reports 31 (8), 2020 | 183 | 2020 |
| Inter-and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling L Brady, M Kriner, I Coleman, C Morrissey, M Roudier, LD True, R Gulati, ... Nature communications 12 (1), 1426, 2021 | 181 | 2021 |
| Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening R Etzioni, R Gulati, L Mallinger, J Mandelblatt Annals of internal medicine 158 (11), 831-838, 2013 | 173 | 2013 |
| Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits I Lansdorp-Vogelaar, R Gulati, AB Mariotto, CB Schechter, ... Annals of internal medicine 161 (2), 104-112, 2014 | 169 | 2014 |
| The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines R Etzioni, R Gulati, A Tsodikov, EM Wever, DF Penson, EAM Heijnsdijk, ... Cancer 118 (23), 5955-5963, 2012 | 166 | 2012 |
| Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends D Telesca, R Etzioni, R Gulati Biometrics 64 (1), 10-19, 2008 | 154 | 2008 |
| Is prostate cancer different in black men? Answers from 3 natural history models A Tsodikov, R Gulati, TM de Carvalho, EAM Heijnsdijk, RA Hunter‐Merrill, ... Cancer 123 (12), 2312-2319, 2017 | 146 | 2017 |
| Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach R Etzioni, R Gulati, S Falcon, DF Penson Medical Decision Making 28 (3), 323-331, 2008 | 146 | 2008 |
| A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer MT Schweizer, K Haugk, JS McKiernan, R Gulati, HH Cheng, JL Maes, ... PloS one 13 (6), e0198389, 2018 | 126 | 2018 |
| Expected population impacts of discontinued prostate‐specific antigen screening R Gulati, A Tsodikov, R Etzioni, RA Hunter‐Merrill, JL Gore, AB Mariotto, ... Cancer 120 (22), 3519-3526, 2014 | 118 | 2014 |
| Limitations of basing screening policies on screening trials: the US Preventive Services Task Force and prostate cancer screening R Etzioni, R Gulati, MR Cooperberg, DM Penson, NS Weiss, ... Medical care 51 (4), 295-300, 2013 | 117 | 2013 |
| Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells C Morrissey, B Gallis, JW Solazzi, BJ Kim, R Gulati, F Vakar-Lopez, ... Anti-cancer drugs 21 (4), 423-432, 2010 | 117 | 2010 |
| Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways L Chéry, HM Lam, I Coleman, B Lakely, R Coleman, S Larson, ... Oncotarget 5 (20), 9939, 2014 | 101 | 2014 |
| Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel HH Cheng, R Gulati, A Azad, R Nadal, P Twardowski, UN Vaishampayan, ... Prostate cancer and prostatic diseases 18 (2), 122-127, 2015 | 100 | 2015 |
